EcoDrugPlus

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSLLEG00000022005
Gene Symbol: PDGFRB
1 View Cross-references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSLLEG00000021129
Gene Symbol: PDGFB
1 View Cross-references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Polo Like Kinase 4

Ensembl ID : ENSLLEG00000005299
Gene Symbol: PLK4
1 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSLLEG00000015662
Gene Symbol: PARP1
1 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSLLEG00000021219
Gene Symbol: KCNN4
1 View Cross-references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSLLEG00000012239
Gene Symbol: KCNJ11
1 View Cross-references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSLLEG00000029614
Gene Symbol: KCNJ2
1 View Cross-references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSLLEG00000017995
Gene Symbol: KCNJ3
1 View Cross-references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSLLEG00000018458
Gene Symbol: KCNJ5
1 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSLLEG00000007336
Gene Symbol: KCNK2
1 View Cross-references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSLLEG00000008124
Gene Symbol: KCNK3
1 View Cross-references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSLLEG00000022991
Gene Symbol: KCNK9
1 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).